Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

Expert Opinion on Investigational Drugs
Carolyn F Deacon, Jens Juul Holst

Abstract

Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects. Preclinical and clinical studies of linagliptin, a new oral antidiabetic agent, including data presented at Scientific Meetings and peer-reviewed studies published since 2007. This article reviews pharmacokinetic and pharmacodynamic characteristics of linagliptin. Linagliptin belongs to a new chemical class of dipeptidyl pepidase-4 (DPP-4) inhibitors, which comprise xanthine-based compounds. It is a potent, long-acting inhibitor with high selectivity for DPP-4 versus the related enzymes DPP-8 and DPP-9. The drug has modest oral availability in humans, but is absorbed rapidly to inhibit plasma DPP-4 activity by > 80% over 24 h. It is not metabolized appreciably in vivo, but binds extensively to plasma proteins, with elimination occurring primarily in the liver. Linagliptin reduces degradation of the incretin hormone glucagon-like peptide-1 and is associated with reduced fasting and postprandial glucose in preclinical and clinical studies. Limited data from longer duration clinical trials show it improves glycemic control in patients with type 2 diabetes. Linagliptin...Continue Reading

References

Feb 18, 2004·Diabetologia·T Vilsbøll, J J Holst
Aug 28, 2004·Diabetes·Carolyn F Deacon
Mar 30, 2007·Clinical Pharmacology and Therapeutics·G A HermanJ A Wagner
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Feb 12, 2008·Biochimica Et Biophysica Acta·Pamela O'Brien, Brendan F O'Connor
May 20, 2008·Bioorganic & Medicinal Chemistry Letters·Matthias EckhardtRalf Lotz
Sep 13, 2008·Molecular and Cellular Endocrinology·Jens Juul HolstCarolyn F Deacon
Dec 17, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Handan HeDan Howard
Jun 30, 2009·Biopharmaceutics & Drug Disposition·Holger FuchsAndreas Greischel
Aug 14, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Dirk ReinholdUte Bank

❮ Previous
Next ❯

Citations

Feb 19, 2011·Reviews in Endocrine & Metabolic Disorders·Rohit KohliThomas H Inge
Mar 14, 2012·Advances in Therapy·Giuseppe PaolissoEdoardo Mannucci
Sep 19, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas RauchTim Heise
Feb 23, 2011·European Journal of Drug Metabolism and Pharmacokinetics·C FriedrichH-J Woerle
Jul 2, 2010·Diabetes, Obesity & Metabolism·A J Scheen
Feb 20, 2012·Journal of Diabetes Investigation·Bo Ahrén
Nov 23, 2012·Kidney & Blood Pressure Research·Markus L AlterBerthold Hocher
May 24, 2013·Diabetology & Metabolic Syndrome·Erika Paniago GuedesFelipe Lauand
Sep 7, 2012·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Lene HoimarkJørgen Rungby
Nov 10, 2013·Vascular Health and Risk Management·Karoline von WebskyBerthold Hocher
Aug 10, 2010·Clinical Pharmacokinetics·André J Scheen
Aug 11, 2012·Clinical Medicine Insights. Endocrinology and Diabetes·Baptist Gallwitz
May 14, 2014·Regulatory Peptides·Vladimer DarsaliaCesare Patrone
Mar 29, 2011·Hospital Practice·Isabelle Bourdel-MarchassonSylvie Dejager
Oct 26, 2011·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Apr 20, 2011·Expert Opinion on Investigational Drugs·Baptist Gallwitz
Dec 18, 2012·Expert Opinion on Drug Safety·Stephanie Aleskow SteinStephen N Davis
Aug 27, 2011·Current Medical Research and Opinion·Scott E Nelson
Dec 27, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Holger FuchsHeinz-Dieter Held
Dec 20, 2011·Bioorganic & Medicinal Chemistry Letters·Jon M SuttonDaniel K Baeschlin
Aug 6, 2015·Scientific Reports·Ruijun HanJohn W Osborn
Sep 16, 2015·Bioorganic & Medicinal Chemistry Letters·Sneha R SagarKamala K Vasu
Feb 11, 2011·British Journal of Clinical Pharmacology·Arne RingKlaus A Dugi
Aug 17, 2010·Diabetes Research and Clinical Practice·John Gerich
Sep 30, 2015·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.